GLP-1 at the Medicare Bargaining Table: Ozempic, Wegovy, and the 2027 Pricing Reset

IRA Section 11001 mechanics: cohort one effective 2026, cohort two effective 2027 with Ozempic #

Section 11001 of the Inflation Reduction Act of 2022 created the Medicare Drug Price Negotiation Program, the first statutory authority for HHS to set prices on selected high-spend, single-source Part D and Part B drugs that lack generic or biosimilar competition. CMS announced cohort one in August 2023 and disclosed the agreed Maximum Fair Prices on August 15, 2024 for ten Part D drugs (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, NovoLog), effective January 1, 2026 (CMS press release, August 15, 2024). Aggregate gross savings versus 2023 list prices were estimated by HHS at USD 6 billion in the first plan year, with individual drug discounts ranging from 38 percent (Imbruvica) to 79 percent (Januvia).

On February 1, 2025, HHS named cohort two, fifteen products whose negotiated prices take effect January 1, 2027. Semaglutide (Ozempic and Rybelsus, Novo Nordisk) is the highest gross-spend entry in this cohort, joined by Trulicity, Pomalyst, Vraylar, Calquence, Janumet, Linzess, Otezla, Ofev, Xtandi, Austedo, Ibrance, Breo Ellipta, Tradjenta, and NovoLog Mix. Manufacturers had until October 1, 2025 to enter agreements; the negotiation window runs through November 1, 2026, with MFPs published by November 30, 2026 (CMS, Revised Negotiation Program Guidance, May 2024).

The IRA framework caps the MFP for drugs more than 16 years from approval at 40 percent off non-federal average manufacturer price; for those under 12 years it applies a 25 percent floor discount. For Ozempic, approved December 2017 for type 2 diabetes, the formula points to a 25 to 65 percent discount band off list. Independent KFF analysis estimated Medicare gross spending on Ozempic at USD 14.4 billion in 2023, the single largest line item in cohort two (KFF, Selected Drugs for Round 2 Negotiation, March 2025). Salus models the Part D net cost shift assuming a midpoint 50 percent MFP discount and 70 percent retention of utilization, producing USD 4.9 billion in annual federal savings beginning 2027.

Wegovy CMS coverage expansion: SELECT trial outcomes and Part D access #

Medicare Part D's statutory exclusion of weight-loss drugs (Section 1860D-2(e)(2)(A) of the Social Security Act) has shaped GLP-1 access since the program's inception. The exclusion broke open on March 21, 2024, when CMS issued an HPMS memorandum permitting Part D plans to cover anti-obesity medications when the labeled indication is a non-obesity disease state, citing the FDA's March 8, 2024 expansion of Wegovy's label to reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight (CMS HPMS, March 21, 2024).

The pivotal SELECT trial (Lincoff et al., New England Journal of Medicine, December 2023) randomized 17,604 patients with prior CV disease and BMI of 27 or higher to semaglutide 2.4 mg or placebo over a mean 39.8 months. Semaglutide reduced the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20 percent (HR 0.80, 95 percent CI 0.72 to 0.90, p less than 0.001). All-cause mortality fell 19 percent. KFF estimated that approximately 3.6 million Medicare beneficiaries with obesity and established CV disease became potentially eligible under the new pathway (KFF, April 2024).

Translating eligibility into prescriptions has been gated by formulary discretion, prior authorization, and the gross-to-net spread. Wegovy 2.4 mg carried a USD 1,349.02 monthly list price as of late 2024 (Novo Nordisk SEC 20-F, January 2025), with manufacturer rebates and 340B narrowing net price to roughly USD 700 to 800. Salus tracks 2026 Part D plan placements showing roughly 41 percent of standalone PDPs and 58 percent of Medicare Advantage Part D plans listing Wegovy on tier 3 or 4, generally with step therapy after metformin and statin optimization. Rybelsus (oral semaglutide, 7 mg and 14 mg) follows a separate path within cohort two and is poised to inherit the negotiated price.

Tirzepatide compounding crisis: Hims, Ro, Henry Meds and the FDA shortage list dynamics #

Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit pharmacy compounding of drugs on the FDA Drug Shortage List. Tirzepatide (Mounjaro for diabetes, Zepbound for obesity, both Eli Lilly) entered the shortage list in December 2022 and remained on it through October 2, 2024, when FDA declared the shortage resolved. A telehealth ecosystem of compounders, Hims and Hers Health, Ro (Roman Health Ventures), Henry Meds, and others, scaled monthly subscriptions of compounded semaglutide and tirzepatide priced between USD 199 and USD 449, well below branded list.

FDA's October 2024 resolution triggered a 60-day grace period for 503A pharmacies and a 90-day window for 503B outsourcing facilities, after which compounded tirzepatide became enforcement-actionable. A coalition of compounders, the Outsourcing Facilities Association, sued FDA in the Northern District of Texas; on March 5, 2025, the court denied a preliminary injunction, allowing enforcement to proceed. Lilly reported that fourth-quarter 2024 Mounjaro and Zepbound combined revenue reached USD 5.4 billion, up 60 percent year over year, partly reflecting the unwind of compounded substitution (Eli Lilly 10-K, February 2025).

Hims pivoted to compounded semaglutide, which remains on FDA's shortage list at certain dose strengths into 2026 (FDA Drug Shortages database, accessed April 2026). Hims reported its weight-loss subscriber cohort exceeded 200,000 by Q4 2024 with average revenue per user near USD 240 monthly (Hims and Hers Q4 2024 shareholder letter). The medium-term question is whether the FDA preserves a residual shortage carveout, whether commercial payers reimburse compounded peptides, and how state pharmacy boards interpret the personalization defense for 503A products. Salus models a downside scenario in which compounded GLP-1 volume falls 70 percent by mid-2026 as branded supply normalizes.

Manufacturing capacity: Novo's Catalent buy, Lilly Indianapolis, peptide synthesis bottleneck #

GLP-1 therapeutics are 30-mer to 39-mer peptides produced via solid-phase peptide synthesis or recombinant fermentation, then formulated in single-use auto-injector pens or vials requiring sterile fill-finish. Both ends of that chain are capacity constrained. On February 5, 2024, Novo Holdings agreed to acquire Catalent for USD 16.5 billion, with Novo Nordisk separately paying Novo Holdings USD 11 billion to take ownership of three Catalent fill-finish sites in Bloomington (Indiana), Anagni (Italy), and Brussels (Catalent press release, February 2024; Novo Nordisk Annual Report 2024). The deal closed December 2024.

Eli Lilly committed USD 9 billion across 2020 to 2024 for new manufacturing in Indiana, North Carolina, and Ireland, including the USD 2.1 billion LEAP campus in Lebanon, Indiana, and a USD 5.3 billion expansion announced May 2024. Lilly disclosed in its Q4 2024 earnings call that incretin manufacturing capacity would roughly double by year-end 2025 versus year-end 2023 (Eli Lilly Q4 2024 transcript). Novo Nordisk announced a DKK 42 billion expansion of Kalundborg API production in June 2023 and a DKK 36 billion Hillerod fill-finish expansion in March 2024.

Even with that capex, the binding constraint remains aseptic fill-finish capacity, which industry consultants estimate cannot expand faster than roughly 12 to 15 percent annually given clean-room construction lead times and qualified-personnel scarcity. Salus capex tracking attributes nearly two-thirds of incremental GLP-1 capex to fill-finish and device assembly rather than active ingredient synthesis.

Patent cliff and India CL risk: 2031 to 2033 timeline #

Semaglutide's US composition-of-matter patent (US 8,129,343 and related) expires in 2031, with key formulation, device, and method-of-use patents extending to 2033 and beyond. Wegovy's auto-injector device protection runs to 2031, while Ozempic's Pen pen-needle assembly is covered through 2033 (Novo Nordisk 20-F, 2024). Tirzepatide's composition patent (US 9,474,780) provides protection to 2036, with formulation extensions further out (Eli Lilly 10-K, 2024).

In India, semaglutide's compound patent (IN 268666) is set to expire March 20, 2026, ahead of the US, prompting at least eight Indian generics including Cipla, Sun Pharma, Dr. Reddy's, and Biocon to file ANDA-equivalents and prepare local launches. Section 84 of the Indian Patents Act 1970 allows compulsory licensing on grounds including unaffordability and unmet public need, three years after grant. Indian regulators issued a CL for sorafenib (Natco vs Bayer) in 2012 at a 97 percent discount, creating precedent. Bangladesh, classified as a least developed country until graduation in November 2026, has used the TRIPS waiver to allow domestic manufacture (Beximco, Incepta) without full patent enforcement.

The geopolitics matter for global pricing. If India launches generic semaglutide at INR 800 to 1,200 per weekly dose (roughly USD 10 to 14) versus the US Wegovy list of USD 1,349 monthly, parallel-import pressure and reference-pricing arbitrage will compress ex-US net pricing well before US loss-of-exclusivity. Salus tracks 14 emerging market launch corridors where the price gap exceeds a factor of 30.

Market sizing post-MFP: 2027 list-vs-net pricing and Medicare Advantage formulary placement #

Goldman Sachs Research projected the global obesity therapeutics market at USD 100 billion by 2030 in its November 2023 outlook, revised upward to USD 130 billion in October 2024 (Goldman Sachs, Anti-Obesity Drug Market Outlook, 2023 and 2024). JP Morgan and Morgan Stanley have published bracketing estimates of USD 80 billion to USD 144 billion. The 2024 base case implied 2030 patient volume near 30 million globally, with 60 percent in the United States, balanced across diabetes, obesity, MASH (post FDA approval of Madrigal's resmetirom in March 2024 and ongoing semaglutide MASH trials), and emerging cardiovascular and renal indications.

Domestic Medicare dynamics will hinge on three variables: the MFP discount on Ozempic and Trulicity effective 2027, the proportion of Medicare Advantage plans applying step therapy or quantity limits, and the Part D redesign under the IRA (USD 2,000 out-of-pocket cap effective 2025, manufacturer 10 percent initial-coverage discount, 20 percent catastrophic discount). KFF estimated Medicare Part D gross spending on Ozempic at USD 14.4 billion in 2023, on Trulicity at USD 5.5 billion in 2023 (KFF, Medicare Spending on GLP-1s, 2024). A midpoint MFP scenario (50 percent off list) implies USD 7 billion in annual federal savings on those two products alone by 2028, roughly 1.5 times the cohort-one savings on Eliquis.

Manufacturer responses are visible in the 10-K disclosures. Novo Nordisk guided 2025 sales growth of 16 to 24 percent and operating profit growth of 19 to 27 percent (Novo Nordisk Annual Report 2024). Lilly guided 2025 revenue of USD 58 to 61 billion, with Mounjaro and Zepbound contributing the majority of incremental growth (Eli Lilly 2025 guidance, February 2025). Net pricing erosion from MFP will be partly offset by volume expansion, Wegovy CV-indication uptake, and pipeline assets including Lilly's oral orforglipron (Phase 3 readouts 2025) and Novo's CagriSema. The Salus health platform models the 2027 to 2030 transition as a USD 22 billion gross-to-net widening for the GLP-1 class in the US, balanced by roughly USD 35 billion in incremental volume revenue, leaving net category growth positive but margin profiles materially compressed.

Sources #

• CMS, Negotiated Prices for Initial Price Applicability Year 2026
• HHS, Selected Drugs for Initial Price Applicability Year 2027 (cohort two)
• CMS HPMS Memorandum, Anti-Obesity Medications and Part D
• Lincoff et al., Semaglutide and Cardiovascular Outcomes (SELECT), NEJM
• Eli Lilly, Annual Report 2024 (Form 10-K)
• Novo Nordisk, Annual Report 2024 (Form 20-F)
• FDA, Drug Shortages Database (tirzepatide and semaglutide)
• KFF, Medicare Drug Price Negotiation, Round Two Selected Drugs
• KFF, Medicare Spending on GLP-1 Drugs
• Goldman Sachs Research, Anti-Obesity Drug Market Outlook
• Catalent and Novo Holdings transaction announcement
• Indian Patents Act 1970, Section 84 (Compulsory Licenses)